Omnicell (NASDAQ:OMCL) Releases FY 2022 Earnings Guidance

Omnicell (NASDAQ:OMCLGet Rating) issued an update on its FY 2022 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $3.85-$3.85 for the period, compared to the consensus estimate of $3.67. The company issued revenue guidance of $1.39 billion-$1.41 billion, compared to the consensus revenue estimate of $1.40 billion.Omnicell also updated its Q2 2022 guidance to $0.82-$0.89 EPS.

Shares of NASDAQ:OMCL opened at $111.78 on Tuesday. The stock has a fifty day simple moving average of $125.54 and a two-hundred day simple moving average of $151.07. The stock has a market capitalization of $4.94 billion, a price-to-earnings ratio of 75.02, a PEG ratio of 2.96 and a beta of 1.20. Omnicell has a 12-month low of $104.32 and a 12-month high of $187.29.

Omnicell (NASDAQ:OMCLGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.43. The business had revenue of $319.00 million during the quarter, compared to analysts’ expectations of $313.98 million. Omnicell had a return on equity of 11.35% and a net margin of 6.00%. The firm’s quarterly revenue was up 26.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.62 earnings per share. Sell-side analysts predict that Omnicell will post 2.43 EPS for the current fiscal year.

Several research firms have recently weighed in on OMCL. Wells Fargo & Company decreased their price target on Omnicell from $188.00 to $158.00 and set an overweight rating for the company in a research note on Tuesday, May 3rd. StockNews.com began coverage on Omnicell in a research note on Thursday, March 31st. They issued a hold rating for the company. Finally, Piper Sandler decreased their price target on Omnicell from $181.00 to $162.00 in a research note on Monday, May 2nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Buy and a consensus price target of $179.17.

Large investors have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC grew its holdings in Omnicell by 6.8% during the fourth quarter. Parametric Portfolio Associates LLC now owns 203,134 shares of the company’s stock valued at $36,653,000 after purchasing an additional 12,850 shares during the period. GAM Holding AG boosted its stake in shares of Omnicell by 25.8% in the fourth quarter. GAM Holding AG now owns 193,029 shares of the company’s stock worth $34,830,000 after acquiring an additional 39,638 shares during the period. California State Teachers Retirement System boosted its stake in shares of Omnicell by 3.4% in the fourth quarter. California State Teachers Retirement System now owns 63,900 shares of the company’s stock worth $11,530,000 after acquiring an additional 2,092 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Omnicell by 1.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 35,761 shares of the company’s stock worth $6,453,000 after acquiring an additional 621 shares during the period. Finally, Stifel Financial Corp boosted its stake in shares of Omnicell by 0.7% in the fourth quarter. Stifel Financial Corp now owns 18,373 shares of the company’s stock worth $3,316,000 after acquiring an additional 132 shares during the period.

Omnicell Company Profile (Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Read More

Earnings History and Estimates for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.